10917 comments

• Հինգշաբթի, 02 Ապրիլի 2026 10:21 posted by phcity Comment Link

  We are a gaggle of volunteers and starting a brand new scheme in our community. Your web site offered us with useful information to work on. You have done an impressive process and our entire group shall be thankful to you.

• Չորեքշաբթի, 01 Ապրիլի 2026 14:01 posted by mba part time malaysia Comment Link

  Thanks for your personal marvelous posting!
  I really enjoyed reading it, you can be a great
  author. I will make certain to bookmark your blog
  and will often come back in the future. I want to encourage you continue your great writing, have a
  nice day!

• Չորեքշաբթի, 01 Ապրիլի 2026 14:00 posted by casino online romania​ Comment Link

  Simply want to say your article is as amazing. The clearness in your post is just excellent and i can assume you
  are an expert on this subject. Well with your permission allow me
  to grab your feed to keep up to date with forthcoming post.
  
  Thanks a million and please keep up the gratifying
  work.

• Չորեքշաբթի, 01 Ապրիլի 2026 13:56 posted by prosteron algeria Comment Link

  I'm extremely impressed with your writing skills and also with the
  layout on your blog. Is this a paid theme or did you modify it yourself?
  Anyway keep up the excellent quality writing, it's rare to see a great blog like this one
  these days.

• Չորեքշաբթի, 01 Ապրիլի 2026 13:45 posted by click here Comment Link

  Good day! This is kind of off topic but I need some
  help from an established blog. Is it very hard to set up your own blog?
  I'm not very techincal but I can figure things out pretty quick.
  
  I'm thinking about making my own but I'm not sure where to
  begin. Do you have any ideas or suggestions? Appreciate it

• Չորեքշաբթի, 01 Ապրիլի 2026 11:57 posted by in-building emergency responder radio systems Comment Link

  After checking out a number of the blog posts on your web site, I
  honestly appreciate your way of blogging. I bookmarked it to my
  bookmark site list and will be checking back soon. Please check out my website as well and tell
  me what you think.

• Չորեքշաբթի, 01 Ապրիլի 2026 11:30 posted by bda and erces Comment Link

  Do you have a spam problem on this site; I also am a blogger, and I was wanting to know your situation; we have created some nice methods and we
  are looking to trade solutions with others, be sure to shoot me an e-mail if interested.

• Երեքշաբթի, 31 Մարտի 2026 13:24 posted by WilliamHoids Comment Link

  Zoya Demidenko: Scientist in Tumor Science
  Zoya Demidenko is a notable investigator connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, establishing a solid foundation in biomedical study.
  Her scholarly work covers several critical areas, including the PI3K/AKT/mTOR signaling pathway, cellular cycle management, cellular aging, and cancer biology. To date, she has authored over 46 academic articles, which have received more than 4,100 citations — a indicator to the significance of her research.
  One of her most notable discoveries lies in elucidating the mechanisms of biological cell aging. Her studies revealed that when the cellular division cycle is halted yet cellular expansion continues, the cells enter senescence. Importantly, Zoya Demidenko demonstrated that this process is inhibited by medication using compounds such as rapamycin.
  Zoya Demidenko has also brought substantially to oncological therapy research, especially in the domain of selective cell protection — a method intended to protecting normal tissue from cytotoxic treatment whilst leaving malignant cells exposed. This method carries considerable hope for lowering the side effects of cancer treatment.
  Throughout her scientific life, Demidenko has collaborated with leading researchers internationally, such as Dr. Mikhail Blagosklonny. Her work appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
  >1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko ranks as a widely cited figure in contemporary biomedical research, whose findings continue to shape our knowledge of the way cells age, respond to treatment, and the ways in which malignant disease might be better combated.
  https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/

• Երեքշաբթի, 31 Մարտի 2026 08:17 posted by winph Comment Link

  Hello! I know this is somewhat off-topic however I had to ask. Does running a well-established blog such as yours take a large amount of work? I am brand new to writing a blog however I do write in my journal everyday. I'd like to start a blog so I can share my personal experience and feelings online. Please let me know if you have any kind of ideas or tips for new aspiring blog owners. Appreciate it!

• Երկուշաբթի, 30 Մարտի 2026 07:59 posted by Lincolnfug Comment Link

  Zoya Demidenko: Scientist in Oncology Studies
  Zoya Demidenko is a notable scholar affiliated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, building a strong base in biomedical investigation.
  Demidenko's scientific work covers several key areas, including the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and malignancy science. Currently, she has authored over 46 peer-reviewed articles, which have accumulated upwards of 4,100 references — a testament to the significance of her work.
  Among her most significant discoveries lies in explaining the mechanisms of cellular senescence. Her studies showed that when the cellular division cycle is halted while cellular growth persists, cells experience senescence. Importantly, Zoya Demidenko showed that this process is controlled with drugs using agents such as mTOR inhibitors.
  Zoya Demidenko has additionally contributed considerably to oncological therapy research, especially in the area of selective cell protection — a method intended to safeguarding non-cancerous tissue from anticancer drugs whilst leaving tumor cells vulnerable. This strategy offers significant potential for diminishing the side effects of oncological therapy.
  Throughout her scientific life, Demidenko has worked with leading scientists globally, including Dr. Mikhail Blagosklonny. Her work appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
  Holding an h-index of 33, Zoya Demidenko ranks as a highly impactful contributor in modern biomedical research, with her findings continue to guide our knowledge of the way biological cells age, interact with treatment, and how malignant disease can be better treated.
  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126